antidepressants/inflammation

TECHNICAL FIELD The present invention relates to a novel agent or composition for use as a muscle-strengthening drug, an anti-inflammatory drug, an antiasthmatic, an antidiarrheal, an antidepressant, or a drug for the treatment of secondary diseases following cerebral infarction (human stroke

BACKGROUND OF THE INVENTION The invention relates to the treatment of inflammatory disorders. Inflammation occurs when tissues are injured by viruses, bacteria, trauma, chemicals, heat, cold or any other harmful stimulus. Chemicals including bradykinin, histamine, serotonin and others are released,

BACKGROUND Damage or disease may affect the somatosensory nervous system and may cause neuropathic pain. Abnormal sensations or pain from normally non-painful stimuli may be associated with neuropathic pain and may occur episodically or continuously. Neuropathic pain sensations may include feelings

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY This application contains, as a separate part of disclosure, a Sequence Listing in computer-readable form (filename: 48812_SeqListing.txt; created Jul. 8, 2014, 659 bytes--ASCII text file) which is incorporated by reference in its

FIELD OF THE INVENTION The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to .beta..sub.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. BACKGROUND

SUMMARY OF THE INVENTION The instant invention is concerned with amide derivatives which are useful as antiobesity and antidiabetic compounds. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the present

SUMMARY OF THE INVENTION The instant invention is concerned with fused piperidine substituted arylsulfonamides which are useful as antiobesity and antidiabetic compounds. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

RELATED APPLICATIONS This application claims priority to U.S. provisional application Ser. No. 60/006,070, filed Oct. 24, 1995, and to U.S. provisional application Ser. No. 60/004,332, filed Sep. 26, 1995. BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and

FIELD OF THE INVENTION The present invention relates to a method of modifying Angiotensin II subtype 1 (AT.sub.1) receptor activity for the treatment of premenstrual syndrome (PMS) and for the mediation and alleviation of pain. More specifically, the present invention relates to the use of AT.sub.1